top of page

CD4 Therapeutics
Unlocking the Power of Regulatory T-Cells for Autoimmune Disease

Diagram showing the selective activation of regulatory T cells (Treg) and inhibition of effector T cells (Teff) by the antibo

A Game-Changer in Autoimmune Therapeutics

CD4 Therapeutics pioneers first-in-class immunotherapy with Tregalizumab, the only monoclonal antibody designed to selectively activate regulatory T-cells (Tregs). With clinical proof-of-concept and high-value indications, we present an exceptionaln investment opportunity in a rapidly expanding market.

​

Addressing High-Unmet Medical Needs
Millions suffer from immune-driven diseases with no approved treatments or high failure rates of existing biologics. Tregalizumab offers a breakthrough solution where conventional therapies fall short.

  • >50% failure rates in second-line biologics

  •  Severe safety concerns with steroids & systemic immunosuppressants

  • No approved therapies for critical indications like immune-driven cancer prevention

Worldwide exclusive licence

In July 2024, T-Balance Therapeutics GmbH and CD4 Therapeutics GmbH, a Munich-based biotech company, signed an exclusive binding term sheet granting CD4 Therapeutics worldwide rights to develop and commercialize Tregalizumab.

Lean, High-Impact Development Strategy

  • Focused Initial Indications (oLP & aGvHD) → De-risked, biomarker-driven approach 

  • Expansion into major autoimmune markets (RA, AD, IBD) based on strong data

  • No direct competitors in Treg activation, creating a defensible market position

  • Strategic Partnerships & Exit Potential → Pharma licensing, M&A, IPO

Competitive Edge: Why CD4 Stands Apart

  • First-in-Class Treg Activator – No approved competitors

  • Strong IP & Regulatory Moat – Orphan designation, biomarker-driven patient selection

  • Proven Leadership – 80+ years of biotech, drug development, and investment success

Investors & Partners – A High-Impact Opportunity

CD4 Therapeutics offers a de-risked investment in next-generation immunotherapy with clear market leadership potential.

​

Why Invest in CD4?

  • First-in-Class Science – The only Treg-activating monoclonal antibody

  • €10B+ Market Potential – Autoimmune & oncology focus

  • De-Risked Clinical Strategy – Proven PoC, targeted success

  • Fast-Track Regulatory Pathways – Orphan drug designation potential

  • Clear Exit Strategies – Licensing, M&A, IPO


Strategic Investment & Exit Opportunities

  • Pharma Licensing & Partnerships – High interest from immunology & oncology leaders

  • Strong Competitive Positioning – No direct competitors in Treg activation

  • Potential for Co-Development & Strategic Alliances

  • High-Value Acquisition or IPO Potential

Join the Next Breakthrough in Immunotherapy

Let’s discuss how you can be part of this high-impact investment. Contact us today and meet the Team!

A Multi-Billion-Euro Market Opportunity

Tregalizumab is positioned to lead in high-need markets with clinical validation and a clear commercialization path.

​

Why This is a €10B+ Opportunity

  • First-mover advantage in key indications

  • High medical need with 50% failure rates in biologics

  • Fast-track regulatory potential in orphan & high-urgency diseases


Key Market Segments:

  • Oral Lichen Planus (oLP): €5B+

  • Acute Graft-versus-Host Disease (aGvHD): €3B+

  • Expansion into RA, AD, IBD (€20B+ total market)

bottom of page